Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk is investigating ziltivekimab in two other studies, one in heart failure and one in patients who have experienced an acute heart attack.
Novo Nordisk is investigating ziltivekimab in two other studies, one in heart failure and one in patients who have experienced an acute heart attack.
The tool’s selection comes shortly after the EDPB released guidelines for clinical trial data anonymisation.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Keeping pace with generative AI in pharmaceutical and healthcare organisations
How wearables can unlock their full potential in clinical research
Clinical trial experts cite trust and regulatory uncertainty as AI barriers
Kidney disease risk higher after Covid infection than after influenza infection